JP2004508280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508280A5 JP2004508280A5 JP2001556226A JP2001556226A JP2004508280A5 JP 2004508280 A5 JP2004508280 A5 JP 2004508280A5 JP 2001556226 A JP2001556226 A JP 2001556226A JP 2001556226 A JP2001556226 A JP 2001556226A JP 2004508280 A5 JP2004508280 A5 JP 2004508280A5
- Authority
- JP
- Japan
- Prior art keywords
- apc
- use according
- protein
- disease
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940096437 Protein S Drugs 0.000 description 5
- 102000029301 Protein S Human genes 0.000 description 5
- 108010066124 Protein S Proteins 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 3
- 101800004937 Protein C Proteins 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 101800001700 Saposin-D Proteins 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18022700P | 2000-02-04 | 2000-02-04 | |
| PCT/US2001/003758 WO2001056532A2 (en) | 2000-02-04 | 2001-02-05 | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508280A JP2004508280A (ja) | 2004-03-18 |
| JP2004508280A5 true JP2004508280A5 (https=) | 2008-03-27 |
Family
ID=22659693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001556226A Pending JP2004508280A (ja) | 2000-02-04 | 2001-02-05 | 活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7074402B2 (https=) |
| EP (1) | EP1255556B1 (https=) |
| JP (1) | JP2004508280A (https=) |
| AT (1) | ATE504310T1 (https=) |
| AU (1) | AU2001238034A1 (https=) |
| CA (1) | CA2398929C (https=) |
| DE (1) | DE60144366D1 (https=) |
| WO (1) | WO2001056532A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040096443A1 (en) * | 2002-03-08 | 2004-05-20 | Traynelis Stephen Francis | Treatment of neurodegenerative diseases and conditions using par1 antagonists |
| JP4351041B2 (ja) | 2001-06-13 | 2009-10-28 | ザ・ユニバーシティ・オブ・シドニー | 傷治癒のための処置および組成物 |
| US20030073636A1 (en) * | 2001-09-19 | 2003-04-17 | Oklahoma Medical Research Foundation | Method of treating diabetes |
| EP1572134B1 (en) * | 2002-09-30 | 2011-09-28 | Zz Biotech L.L.C. | Protein s for use as a neuroprotective agent |
| WO2004056309A2 (en) * | 2002-12-05 | 2004-07-08 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| ES2504365T3 (es) * | 2002-12-05 | 2014-10-08 | Zz Biotech L.L.C. | La actividad neuroprotectora de la proteína C activada es independiente de su actividad anticoagulante |
| US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
| US9192657B2 (en) * | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| JP2008507561A (ja) * | 2004-07-23 | 2008-03-13 | ザ ユニバーシティ オブ ロチェスター | 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害 |
| WO2006072137A1 (en) * | 2005-01-07 | 2006-07-13 | Northern Sydney And Central Coast Area Health Service | Treatment for autoimmune and inflammatory conditions |
| US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| EP2182978A4 (en) | 2007-07-20 | 2012-03-21 | Sanomune Inc | TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN |
| US8257700B2 (en) * | 2008-02-05 | 2012-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Proteomic analysis of active multiple sclerosis lesions |
| CN102458454A (zh) * | 2009-04-22 | 2012-05-16 | 森诺姆尼有限公司 | 用于治疗亨廷顿病的组织激肽释放酶 |
| JP6273272B2 (ja) | 2012-07-04 | 2018-01-31 | ジージー バイオテック エルエルシー | 炎症性皮膚障害の治療 |
| CN104122396A (zh) * | 2013-04-23 | 2014-10-29 | 中国科学院上海生命科学研究院 | 维生素k依赖性蛋白s作为糖尿病标志物的应用 |
| CA2946032C (en) | 2014-04-16 | 2022-06-14 | Zz Biotech Llc | Use of apc analogue for wound healing |
| JP2017513944A (ja) | 2014-04-16 | 2017-06-01 | ジージー バイオテック エルエルシー | 異常な皮膚瘢痕化の治療 |
| CN105806818B (zh) * | 2016-04-01 | 2019-11-22 | 南京医科大学 | 检测血小板nmda受体活性的方法及其应用 |
| US11820833B2 (en) | 2016-06-05 | 2023-11-21 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Peptides that inhibit binding of EPCR to its ligand to treat inflammation |
| AU2018230478B2 (en) | 2017-03-09 | 2025-01-23 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
| US20230141921A1 (en) * | 2020-03-24 | 2023-05-11 | Talengen International Limited | Method and medicine for treating huntington's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084274A (en) * | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US5009889A (en) * | 1987-12-31 | 1991-04-23 | Oklahoma Medical Research Foundation | Treatment of dysfunctional vascular endothelium using activated protein C |
| AT402153B (de) * | 1989-06-26 | 1997-02-25 | Immuno Ag | Protein-s-hältige pharmazeutische präparation |
| US5254532A (en) * | 1989-06-26 | 1993-10-19 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same |
| EP0872245B1 (en) * | 1997-03-24 | 2006-03-08 | Eli Lilly And Company | Methods for treating vascular disorders with activated Protein C |
| WO1998055142A1 (en) * | 1997-06-05 | 1998-12-10 | Eli Lilly And Company | Methods for treating thrombotic disorders |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
-
2001
- 2001-02-05 AT AT01910427T patent/ATE504310T1/de not_active IP Right Cessation
- 2001-02-05 US US09/777,484 patent/US7074402B2/en not_active Expired - Fee Related
- 2001-02-05 EP EP01910427A patent/EP1255556B1/en not_active Expired - Lifetime
- 2001-02-05 WO PCT/US2001/003758 patent/WO2001056532A2/en not_active Ceased
- 2001-02-05 JP JP2001556226A patent/JP2004508280A/ja active Pending
- 2001-02-05 DE DE60144366T patent/DE60144366D1/de not_active Expired - Lifetime
- 2001-02-05 AU AU2001238034A patent/AU2001238034A1/en not_active Abandoned
- 2001-02-05 CA CA2398929A patent/CA2398929C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004508280A5 (https=) | ||
| Kalimo et al. | Effects of severe hypoglycemia on the human brain neuropathological case reports | |
| WO2009104932A3 (ko) | 복합제제 | |
| DE69933049T2 (de) | Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung | |
| JP2007514750A5 (https=) | ||
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| JP2002532392A5 (https=) | ||
| JP2011079860A (ja) | 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用 | |
| JP2005520778A5 (https=) | ||
| JP2005501110A5 (https=) | ||
| Naritoku et al. | Intravenous loading of valproate for epilepsy | |
| RU2009110273A (ru) | Способ уменьшения повреждения нервных клеток | |
| JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
| JP2010531861A (ja) | パーキンソン病治療薬 | |
| JP2010531862A (ja) | パーキンソン病治療薬 | |
| Katsuta et al. | The neuroprotective effect of the novel noncompetitive NMDA antagonist, FR115427 in focal cerebral ischemia in rats | |
| RU2674653C2 (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii | |
| CN110433160A (zh) | 一种治疗肝纤维化的化合物及其应用 | |
| Rosenow et al. | Recent and future advances in the treatment of status epilepticus | |
| Komatsu et al. | Effect of hemoglobin vesicle, a cellular-type artificial oxygen carrier, on middle cerebral artery occlusion-and arachidonic acid-induced stroke models in rats | |
| Shoulson et al. | Clonidine and the anti-parkinsonian response to L-DOPA or piribedil | |
| CN105451727A (zh) | 用于预防和/或治疗i型慢性创伤性脑病的方法 | |
| DE602004012152T2 (de) | Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen | |
| TWI474825B (zh) | 治療神經損傷之醫藥套組 | |
| JPH06263636A (ja) | 脳または高次神経疾患治療剤 |